3rd Quarter - Report — NATIONAL KIDNEY FOUNDATION for NATIONAL KIDNEY FOUNDATION (2018)

Firm

NATIONAL KIDNEY FOUNDATION

Client

NATIONAL KIDNEY FOUNDATION

Income

—

Expenses

$100,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2019 Appropriations for the Department of Health and Human Services (NIH, CDC, HRSA); Food and Drug Administration; Department of Veterans Affairs, Indian Health Service, Department of Defense (medical research)

Lobbyist	Covered position, as disclosed
TONYA SAFFER	—
TROY ZIMMERMAN	—

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); SENATE; Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ); Labor, Dept of (DOL)

Health Issues HCR

Initiatives to increase and facilitate organ donation and transplantation, including H.R.1270 (Living Donor Protection Act) and build support for a Senate companion bill Prescription Drug Pricing H.R. 2644 and S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017 Health and Human Services Million Hearts initiative Health and Human Services KidneyX initiative Comments on Patient Focused Drug Development Draft Guidance for Industry Comments on Physician-focused Payment Model Technical Advisory Committee preliminary review and model consideration process Management of the Patient Protection and Affordable Care Act Repeal and Replacement of Affordable Care Act

Lobbyist	Covered position, as disclosed
ANDREW W. FULLERTON New	—
TONYA SAFFER	—
TROY ZIMMERMAN	—

Contacted: Labor, Dept of (DOL); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE; Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA)

Bills named: H.R. 2644 (115th), S. 1890 (115th), H.R. 1270 (115th)

Medicare/Medicaid MMM

Initiatives to support early detection and management of Chronic Kidney Disease (H.R. 3867) Proposed Alternative Payment Model for Chronic Kidney Disease care Comments on ESRD Prospective Payment System and Quality Incentive Program proposed rule Comments on payment policies under the Physician Fee Schedule; Medicare Shared Savings Program; and Quality Payment Program Increased utilization of home kidney dialysis Medicare coverage of immunosuppressive drugs for kidney transplant recipients Increased utilization of kidney discards for transplantation

Lobbyist	Covered position, as disclosed
ANDREW W. FULLERTON New	—
TONYA SAFFER	—
TROY ZIMMERMAN	—

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Labor, Dept of (DOL); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC)

Bills named: H.R. 3867 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.